Abstract: The present invention provides for a composition comprising: (a) a first host cell capable of producing L-DOPA; and (b) a modified host cell is capable of converting L-DOPA into hydroxytyrosol (HTy); wherein any one or both of the first host cell and second host cell is a genetically modified host cell.

Abstract: Provided is a method capable of shortening the time required for analysis and capable of analyzing various substances produced by microorganisms. A method for analyzing a metabolite of a microorganism according to the present invention includes: a step of supplying a mobile phase including carbon dioxide in a liquid state, a subcritical state, or a supercritical state to a container in which a microorganism cultured in a medium is contained together with the medium, to move a component of a metabolite of the microorganism present in the microorganism and the medium to the mobile phase; a step of introducing a mobile phase to which a component of the metabolite has moved into a column; and a step of performing mass spectrometry on a component of the metabolite contained in the mobile phase that has passed through the column.

Abstract: A method for producing an objective protein and a method for producing a disaccharide are provided. An objective protein is produced by culturing Talaromyces cellulolyticus in a culture medium containing an expression inducer such as gentiobiose. A disaccharide is produced from a saccharide raw material by enzymatic conversion using a disaccharide synthesizing enzyme.

Abstract: A method for producing an objective protein and a method for producing a disaccharide are provided. An objective protein is produced by culturing Talaromyces cellulolyticus in a culture medium containing an expression inducer such as gentiobiose. A disaccharide is produced from a saccharide raw material by enzymatic conversion using a disaccharide synthesizing enzyme.

Abstract: The present invention provides for a composition comprising: (a) a first host cell capable of producing L-DOPA; and (b) a modified host cell is capable of converting L-DOPA into hydroxytyrosol (HTy); wherein any one or both of the first host cell and second host cell is a genetically modified host cell.

Abstract: To provide a pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt; monohydric alcohol fatty acid esters; dibasic acid diesters; lower alkylene carbonates; butylene glycol; diethylene glycol mono(lower)alkyl ethers; and thickeners. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.